Multiple Myeloma
Two new denosumab biosimilars earn FDA approval
The FDA has approved two new biosimilars of denosumab for all indications of the reference medications Prolia and Xgeva, according to a press release from Celltrion.
VIDEO: Study enrollment underway that could ‘change the treatment paradigm for myeloma’
VIDEO: Importance of caregiver support for patients with myeloma receiving CAR-T
FDA approves two new biosimilars of denosumab
The FDA has approved two new biosimilars of denosumab to treat osteoporosis, increase bone mass, prevent skeletal-related events for people with multiple myeloma and other indications, Samsung Bioepis announced.
VIDEO: Regular monitoring key to avoiding myeloma relapse
In this video, Sham Mailankody, MBBS discusses methods to stay aware of the threat of multiple myeloma relapse.
VIDEO: Logistical issues complicate relapsed/refractory myeloma treatment
In this video, Sham Mailankody, MBBS discusses the specific challenges that come with treating relapsed/refractory multiple myeloma.
VIDEO: New immunotherapies developing for multiple myeloma
In this video, Sham Mailankody, MBBS discusses the current state of the pipeline for developing multiple myeloma treatments.
VIDEO: Curative treatment still a goal for multiple myeloma
In this video, Sham Mailankody, MBBS discusses the biggest unmet needs in multiple myeloma treatment.